Combination product jurisdiction
This article was originally published in The Gray Sheet
Executive Summary
FDA's 1991 Intercenter Agreements "should not be independently relied upon," although they "may still be helpful in certain situations," OCP advises in a FDL-1jurisdictional update posted on its website Sept. 6. The ICAs provided some guidance for how combination products would be regulated based on the "way the world was in 1991," OCP Director Mark Kramer said, but his office is working to create processes that are "more translatable to the future." OCP recently issued guidance on writing a request for center designation, incorporating the agency's primary mode of action 1final rule. It also posted two concept papers Sept. 6...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.